If you have been reading about heptapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
| Property | Value | Notes |
|---|---|---|
| Primary research models | Rodent studies | Largest share of published data |
| Reported markers | BDNF and NGF expression | Measured mainly in animal tissue |
| Common administration | Intranasal | Matches the registered formulation |
| Blood residence time | Minutes | Rapid enzymatic degradation |
| Evidence quality | Small trials, limited replication | Noted repeatedly in reviews |
Verification of a supplied batch generally combines a certificate of analysis with independent testing, because certificates are self-reported documents. A typical package includes a chromatographic trace, a mass spectrum, and a stated water or counter-ion content. Batch-to-batch consistency matters more than a single purity figure when results are compared across experiments. No single mandatory standard governs research-grade peptide release, so laboratories are expected to define their own acceptance criteria. Residual trifluoroacetate from purification is a frequently overlooked counter-ion.
Lyophilized material is chemically stable for extended periods when kept dry, cold, and protected from light. The powder is hygroscopic, so vials should be warmed to room temperature before opening to reduce condensation on the contents. Once dissolved, the peptide is far less stable because peptide bonds are susceptible to hydrolysis and the methionine residue can oxidize. Solutions are typically aliquoted and held at 2-8 °C for short intervals or frozen for longer ones, and repeated freeze-thaw cycles should be avoided.
Routine characterization relies on reversed-phase high-performance liquid chromatography to establish purity and on mass spectrometry to confirm molecular identity. Electrospray ionization and matrix-assisted laser desorption ionization are both used for mass verification. Amino acid analysis and peptide mapping can detect sequence errors. Common impurities include truncated sequences, methionine sulfoxide formed by oxidation, and deamidated products. Chromatograms are usually recorded near 214 nm, where the peptide backbone absorbs, and purity is reported as the percentage area of the principal peak.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Published research has focused mainly on neurological and cognitive endpoints in animal models, with proposed mechanisms involving brain-derived neurotrophic factor and related signalling pathways. A substantial share of the human data originates from a limited number of research groups, and independent replication in other countries remains sparse. Regulatory status reflects that distribution: the peptide is registered as a medicine in Russia and appears in some neighbouring markets, while elsewhere it is handled as a research chemical without approved therapeutic labelling. Questions about dose-response relationships, long-term effects, and comparability across studies are still open.
Lyophilised powder is normally kept at -20 °C in a desiccated container, with some suppliers recommending -80 °C for long-term archival storage. Repeated freeze-thaw cycles are the most common cause of avoidable loss, so aliquoting before freezing reduces variability between working sessions. Dissolved peptide is far less stable than the dry solid and is usually prepared fresh or held briefly at 4 °C. Aqueous solutions support both hydrolysis of the backbone and oxidation of the N-terminal methionine, and these two routes dominate degradation under ordinary laboratory conditions.
Identity and purity are confirmed with reversed-phase high-performance liquid chromatography, typically monitored at 214 nanometres where the peptide bond absorbs. Mass spectrometry, either electrospray or MALDI-TOF, verifies molecular mass against the theoretical value and detects truncation or adduct formation. Amino acid analysis and peptide mapping provide additional confirmation when required. The most frequently reported impurities are deletion sequences from incomplete coupling, methionine sulfoxide from oxidation, and dimeric species formed through non-covalent aggregation. Impurity profiles depend strongly on the synthesis and purification route chosen by the producer.
=== Churches === Le Havre Cathedral: the first stone of the building was laid in 1536. It is the seat of the Bishop of Le Havre. Church of Saint Joseph, one of the most recognized symbols of the city. The belltower is one of the tallest in France, rising to a height of 107 metres. It was designed by Auguste Perret. Church of Saint Michel Church of Saint Vincent Church of Saint François Church of St. Anne Church of Saint Marie Chapel of Saint Michel d'Ingouville (15th century) Graville Abbey, a monastery dedicated to Sainte Honorine, set in grounds on the northern bank of the Seine River. Presbyterian Reform Church (Église Réformée), 47 rue Anatole France, built in 1857, bombed in 1941, the roof and ceiling were rebuilt in 1953 by two architects from the famous Auguste Perret office: Jacques Lamy and Gérard Dupasquier, The only building in town offering both ancient and the new Perret school of architecture in the same building. Holy Office each Sunday morning at 10.30.
=== Stem cells === Levels of p53 play an important role in the maintenance of stem cells throughout development and the rest of human life. In human embryonic stem cells (hESCs)s, p53 is maintained at low inactive levels. This is because activation of p53 leads to rapid differentiation of hESCs. Studies have shown that knocking out p53 delays differentiation and that adding p53 causes spontaneous differentiation, showing how p53 promotes differentiation of hESCs and plays a key role in cell cycle as a differentiation regulator. When p53 becomes stabilized and activated in hESCs, it increases p21 to establish a longer G1. This typically leads to abolition of S-phase entry, which stops the cell cycle in G1, leading to differentiation. Work in mouse embryonic stem cells has recently shown however that the expression of P53 does not necessarily lead to differentiation. p53 also activates miR-34a and miR-145, which then repress the hESCs pluripotency factors, further instigating differentiation. In adult stem cells, p53 regulation is important for maintenance of stemness in adult stem cell niches. Mechanical signals such as hypoxia affect levels of p53 in these niche cells through the hypoxia inducible factors, HIF-1α and HIF-2α. While HIF-1α stabilizes p53, HIF-2α suppresses it. Suppression of p53 plays important roles in cancer stem cell phenotype, induced pluripotent stem cells and other stem cell roles and behaviors, such as blastema formation. Cells with decreased levels of p53 have been shown to reprogram into stem cells with a much greater efficiency than normal cells.
== Antidote == In case of a bite from the black mamba, the victim should be treated according to a standard protocol. The most important part of this treatment is the intravenous injection of a polyvalent antivenom. South African Vaccine Producers produces this antivenom. Polyvalent means that it can be used for different snakebites: vipers, mambas and cobras. Large quantities of the antivenom must be injected to counter the effects of the venom. The polyvalent antivenin is produced by injecting horses with adapted venom. The venom is first detoxified to prevent too much damage and death. This is mostly done by complexing the venom with an aldehyde like formalin. The venom is also administered with an adjuvant, like aluminium hydroxide or sodium alginate, to stimulate the immunological response. When the venom is injected, the body will produce antibodies. These will bind components – the variability of peptides – of the venom, which prevent further activity of the molecule and are ultimately removed by the immune system of the body. These antibodies are collected and purified from the blood and then packaged in mostly a liquid form. Horses are used because of the large blood volume. The final antivenom product expires after 5 years and needs to preferentially be kept cool, 4-8 °C. It can, however, survive different environmental situations for some weeks to months, without losing its potency. Because several venoms of different snakes are injected over time, the horse will develop different antibodies against all the venoms.
In biology, a pair bond is the strong affinity that develops in some species between a mating pair, often leading to the production and rearing of young and potentially a lifelong bond. Pair-bonding is a term coined in the 1940s that is frequently used in sociobiology and evolutionary biology circles. The term often implies either a lifelong socially monogamous relationship or a stage of mating interaction in socially monogamous species. It is sometimes used in reference to human relationships.
== Biography == Meyer was born on 4 September 1899 in Kerpen, Germany. He studied medicine and received his Ph.D. from the University of Cologne in 1924. He moved to Berlin and received a Ph.D. in chemistry from the Kaiser Wilhelm Society in 1927. In 1930, Herbert Evans invited Meyer to work as assistant professor at the University of California, Berkeley. He then moved to New York and worked at Columbia University, doing research on hyaluronan. From 1967 to 1976, Meyer was a professor of Biochemistry at Yeshiva University in New York City before returning to Columbia University as an emeritus professor. A resident of Teaneck, New Jersey, Meyer died at the age of 90 on 18 May 1990, at a nursing home in nearby Cresskill.
Sources: en.wikipedia.org
=== Applications === Libraries of peptide aptamers have been used as "mutagens", in studies in which an investigator introduces a library that expresses different peptide aptamers into a cell population, selects for a desired phenotype, and identifies those aptamers that cause the phenotype. The investigator then uses those aptamers as baits, for example in yeast two-hybrid screens to identify the cellular proteins targeted by those aptamers. Such experiments identify particular proteins bound by the aptamers, and protein interactions that the aptamers disrupt, to cause the phenotype. In addition, peptide aptamers derivatized with appropriate functional moieties can cause specific post-translational modification of their target proteins, or change the subcellular localization of the targets.
It is important to investigate the rate at which the solute is transferred between the two phases, in some cases by an alteration of the contact time it is possible to alter the selectivity of the extraction. For instance, the extraction of palladium or nickel can be very slow because the rate of ligand exchange at these metal centers is much lower than the rates for iron or silver complexes.
== ISO 4500 - ISO 4999 == ISO 4548 Methods of test for full-flow lubricating oil filters for internal combustion engines ISO 4548-7:2012 Part 7: Vibration fatigue test ISO 4551:1987 Ferroalloys – Sampling and sieve analysis ISO 4552 Ferroalloys – Sampling and sample preparation for chemical analysis ISO 4552-1:1987 Part 1: Ferrochromium, ferrosilicochromium, ferrosilicon, ferrosilicomanganese, ferromanganese ISO 4552-2:1987 Part 2: Ferrotitanium, ferromolybdenum, ferrotungsten, ferroniobium, ferrovanadium ISO 4570 Tyre valve threads ISO 4578 Adhesives — Determination of peel resistance of high-strength adhesive bonds — Floating-roller method ISO 4582 Plastics — Determination of changes in colour and variations in properties after exposure to daylight under glass, natural weathering or laboratory light sources ISO 4587 Adhesives — Determination of tensile lap-shear strength of rigid-to-rigid bonded assemblies ISO 4618:2014 Paints and varnishes – Terms and definitions ISO 4628 Paints and varnishes – Evaluation of degradation of coatings – Designation of quantity and size of defects, and of intensity of uniform changes in appearance ISO 4628-1 General introduction and designation system ISO 4628-2 Assessment of degree of blistering ISO 4628-3 Assessment of degree of rusting ISO 4628-4 Assessment of degree of cracking ISO 4628-5 Assessment of degree of flaking ISO 4628-6 Assessment of degree of chalking by tape method ISO 4628-7 Assessment of degree of chalking by velvet method ISO 4628-8 Assessment of degree of delamination and corrosion around a scribe ISO 4628-10 Assessment of degree of filiform corrosion ISO 4648:1991 Rubber, vulcanized or thermoplastic — Determination of dimensions of test pieces and products for test purposes [Withdrawn: replaced with ISO 23529] ISO 4661 Rubber, vulcanized — Preparation of samples and test pieces ISO 4661-1:1993 Rubber, vulcanized or thermoplastic — Preparation of samples and test pieces — Part 1: Physical tests [Withdrawn: replaced with ISO 23529] ISO 4661-2:2018 Rubber, vulcanized — Preparation of samples and test pieces — Part 2: Chemical tests ISO 4683 Raw sheep skins ISO 4683-1:1998 Part 1: Descriptions of defects ISO 4720:2009 Essential oils – Nomenclature ISO 4730:2017 Essential oil of Melaleuca, terpinen-4-ol type (Tea Tree oil) ISO 4786:1977 Enclosed-scale adjustable-range thermometers [Withdrawn without replacement] ISO 4787:2010 Laboratory glassware – Volumetric instruments – Methods for testing of capacity and for use ISO 4788:2005 Laboratory glassware – Graduated measuring cylinders ISO 4791 Laboratory apparatus – Vocabulary relating to apparatus made essentially from glass, porcelain or vitreous silica ISO 4791-1:1985 Part 1: Names for items of apparatus ISO 4795:1996 Glass for thermometer bulbs ISO 4801:1979 Glass alcoholometers and alcohol hydrometers not incorporating a thermometer ISO 4805:1982 Laboratory glassware – Thermo-alcoholometers and alcohol-thermohydrometers ISO 4824:1993 Dentistry — Ceramic denture teeth [Withdrawn: replaced with ISO 22112] ISO 4831:2006 Microbiology of food and animal feeding stuffs – Horizontal method for the detection and enumeration of coliforms – Most probable number technique ISO 4832:2006 Microbiology of food and animal feeding stuffs – Horizontal method for the enumeration of coliforms – Colony-count technique ISO 4833 Microbiology of the food chain – Horizontal method for the enumeration of microorganisms ISO 4833-1:2013 Part 1: Colony count at 30 degrees C by the pour plate technique ISO 4833-2:2013 Part 2: Colony count at 30 degrees C by the surface plating technique ISO 4848:1980 Concrete — Determination of air content of freshly mixed concrete — Pressure method [Withdrawn: replaced with ISO 1920-2] ISO 4858:1982 Wood — Determination of volumetric shrinkage [Withdrawn: replaced with ISO 13061-14] ISO 4859:1982 Wood — Determination of radial and tangential swelling [Withdrawn: replaced with ISO 13061-15] ISO 4860:1982 Wood — Determination of volumetric swelling [Withdrawn: replaced with ISO 13061-16] ISO 4866:2010 Mechanical vibration and shock – Vibration of fixed structures – Guidelines for the measurement of vibrations and evaluation of their effects on structures ISO 4871:1996 Acoustics – Declaration and verification of noise emission values of machinery and equipment ISO/IEC 4873:1991 Information technology – ISO 8-bit code for information interchange – Structure and rules for implementation ISO 4875 Metal-cutting band saw blades ISO 4875-1:2006 Part 1: Vocabulary ISO 4880:1997 Burning behaviour of textiles and textile products – Vocabulary ISO 4882:1979 Office machines and data processing equipment – Line spacings and character spacings ISO 4885:2017 Ferrous materials – Heat treatments – Vocabulary ISO 4892 Plastics – Methods of exposure to laboratory light sources ISO 4902:1989 Information technology – Data communication – 37-pole DTE/DCE interface connector and contact number assignments ISO 4903:1989 Information technology – Data communication – 15-pole DTE/DCE interface connector and contact number assignments ISO/IEC 4909:2006 Identification cards – Financial transaction cards – Magnetic stripe data content for track 3 ISO 4921:2000 Knitting – Basic concepts – Vocabulary ISO/IEC 4922-1 Information security — Secure multiparty computation ISO/IEC 4922-1:2023 Part 1: General ISO 4977 Double cold-reduced electrolytic tinplate ISO 4977-1:1984 Part 1: Sheet [Withdrawn: replaced with ISO 11949] ISO 4977-2:1984 Part 2: Coil for subsequent cutting into sheets [Withdrawn: replaced with ISO 11949]
“A New Pentacyclic Pyrylium Fluorescent Probe that Responds to pH Imbalance During Apoptosis”. Chem. Sci., 2020,11, 12695-12700. https://doi.org/10.1039/D0SC02623A. A. Mal, S. Vijayakumar, R. K. Mishra, J. Jacob, R. S. Pillai, B. S. Dileep Kumar and Ajayaghosh, Ayyappanpillai (2020). “Supramolecular Surface Charge Regulation in Ionic Covalent Organic Nanosheets for Reversible Exfoliation and Controlled Bacterial Growth”. Angew. Chem., Int. Ed. 2020, 59, 8713-8719. https://doi.org/10.1002/anie.201912363. G, Das.; S, Cherumukkil.; A, Padmakumar.; V, B, Banakar.; V, K, Praveen.; and Ajayaghosh, Ayyappanpillai (2021). “Tweaking a BODIPY Spherical Self-Assembly to 2D Supramolecular Polymers Facilitates Excited State Cascade Energy Transfer”. Angew. Chem. Int. Ed. 2021, 60, 7851-7938. https://doi.org/10.1002/ange.202015390. A, Nirmala.; I, Mukkatt.; S, Shankar.; and Ajayaghosh, Ayyappanpillai (2021). “Thermochromic Color Switching to Temperature Controlled Volatile Memory and Counter Operations with Metal-Organic Complexes and Hybrid Gels”. Angew. Chem., Int. Ed. 2021, 60, 455-465. https://doi.org/10.1002/anie.202011580. I, Mukkatt.; A, P, Mohanachandran.; A, Nirmala.; D, Patra.; P, A, Sukumaran.; R, S, Pillai.; R, B, Rakhi.; S, Shankar.; and Ajayaghosh, Ayyappanpillai (2022). “Tunable Capacitive Behavior in Metallopolymer-based Electrochromic Thin Film Supercapacitors”. ACS Appl. Mater. Interfaces, 2022, 14, 31900-31910. https://doi.org/10.1021/acsami.2c05744
=== Liver === The liver parenchyma is the functional tissue of the organ made up of around 80% of the liver volume as hepatocytes. The other main type of liver cells are non-parenchymal. Non-parenchymal cells constitute 40% of the total number of liver cells but only 6.5% of its volume.
Sources: en.wikipedia.org
== History == Amitriptyline was developed by the American pharmaceutical company Merck in the late 1950s. In 1958, Merck approached several clinical investigators proposing to conduct clinical trials of amitriptyline for schizophrenia. One of these researchers, Frank Ayd, instead, suggested using amitriptyline for depression. Ayd treated 130 patients and, in 1960, reported that amitriptyline had antidepressant properties similar to another, and the only known at the time, tricyclic antidepressant imipramine. Following this, the US Food and Drug Administration approved amitriptyline for depression in 1961. In Europe, due to a quirk of the patent law at the time allowing patents only on the chemical synthesis but not on the drug itself, Roche and Lundbeck were able to independently develop and market amitriptyline in the early 1960s. According to research by a historian of psychopharmacology David Healy, amitriptyline became a much bigger selling drug than its precursor imipramine because of two factors. First, amitriptyline has a much stronger anxiolytic effect. Second, Merck conducted a marketing campaign raising clinicians' awareness of depression as a clinical entity. Amitriptyline is no longer sold under the brand name Elavil.
A pre-injection tuberculin skin test is usually carried out before administering the BCG vaccine. A reactive tuberculin skin test is a contraindication to BCG due to the risk of severe local inflammation and scarring; it does not indicate immunity. BCG is also contraindicated in certain people who have IL-12 receptor pathway defects. BCG is given as a single intradermal injection at the insertion of the deltoid. If BCG is accidentally given subcutaneously, then a local abscess may form (a "BCG-oma") that can sometimes ulcerate, and may require treatment with antibiotics immediately, otherwise without treatment it could spread the infection, causing severe damage to vital organs. An abscess is not always associated with incorrect administration, and it is one of the more common complications that can occur with the vaccination. Numerous medical studies on the treatment of these abscesses with antibiotics have been done with varying results, but the consensus is once pus is aspirated and analysed, provided no unusual bacilli are present, the abscess will generally heal on its own in a matter of weeks. The characteristic raised scar that BCG immunization leaves is often used as proof of prior immunization. This scar must be distinguished from that of smallpox vaccination, which it may resemble. When given for bladder cancer, the vaccine is not injected through the skin but is instilled into the bladder (intravesical) through the urethra using a soft catheter.
=== Conversion of pyruvate into oxaloacetate for the citric acid cycle === Pyruvate molecules produced by glycolysis are actively transported across the inner mitochondrial membrane, and into the matrix where they can either be oxidized and combined with coenzyme A to form CO2, acetyl-CoA, and NADH, or they can be carboxylated (by pyruvate carboxylase) to form oxaloacetate. This latter reaction "fills up" the amount of oxaloacetate in the citric acid cycle, and is therefore an anaplerotic reaction (from the Greek meaning to "fill up"), increasing the cycle's capacity to metabolize acetyl-CoA when the tissue's energy needs (e.g. in heart and skeletal muscle) are suddenly increased by activity. In the citric acid cycle all the intermediates (e.g. citrate, iso-citrate, alpha-ketoglutarate, succinate, fumarate, malate and oxaloacetate) are regenerated during each turn of the cycle. Adding more of any of these intermediates to the mitochondrion therefore means that that additional amount is retained within the cycle, increasing all the other intermediates as one is converted into the other. Hence the addition of oxaloacetate greatly increases the amounts of all the citric acid intermediates, thereby increasing the cycle's capacity to metabolize acetyl CoA, converting its acetate component into CO2 and water, with the release of enough energy to form 11 ATP and 1 GTP molecule for each additional molecule of acetyl CoA that combines with oxaloacetate in the cycle.
== Clinical significance == Several studies resulting in an initial information search on C3orf52 focused on the likely involvement of this gene in lipase H-mediated lysophosphatidic acid biosynthesis, a step in hair-follicle formation. Evidence shows that decreased expression of C3orf52 has been linked to localized autosomal recessive hypotrichosis, a condition resulting in the absence of hair. There were three relevant single-nucleotide polymorphisms found with clinical significance linked to hypotrichosis 15 (rs764787339, rs2472299130, rs545208237) (Table 2). Apart from articles on the involvement of C3orf52 in hair loss, PubMed and Google Scholar provided a couple of other potential linkages between this gene and diseases, specifically a variety of cancers. One of the more eye-catching articles found associations of this gene in the development of multifocal and multicentric breast cancer, and is looking into it as a current marker for distinguishing multifocal and multicentric breast cancer from unifocal breast cancers. Another study proposes looking at C3orf52 as a potential marker as a prognosis gene of cancer in a study looking at DNA copy number variations, which are common in cancer cells. Additionally, C3orf52 is linked to be downregulated in clear-cell renal cell carcinoma, and its reduced expression was linked to later disease stage and poorer overall survival of clear-cell renal cell carcinoma patients.
=== Clinical management === A king cobra's bite, and subsequent envenomation, is an immediate medical emergency in humans or domesticated animals, as, if not treated as soon as possible, death can occur in as little as 30 minutes. Local symptoms include dusky discolouration of skin, edema and pain; in severe cases, swelling extends proximally, with necrosis and tissue sloughing that may require amputation. Onset of general symptoms follows while the venom is targeting the victim's central nervous system, resulting in blurred vision, vertigo, drowsiness, and eventual paralysis. If not treated promptly, it may progress to cardiovascular collapse and, subsequently, coma. Death soon follows due to respiratory failure, among other simultaneous and varied system and organ failures. Polyvalent antivenom of equine origin is produced by Haffkine Institute and King Institute of Preventive Medicine and Research in India. A polyvalent antivenom produced by the Thai Red Cross Society can effectively neutralise venom of the king cobra. Proper and immediate treatments are critical to avoid death. Successful precedents include a client who recovered and was discharged in 10 days after being treated by accurate antivenom and inpatient care. It can deliver up to 420 mg venom in dry weight (400–600 mg overall) per bite, with a LD50 toxicity in mice of 1.28 mg/kg through intravenous injection, 1.5 to 1.7 mg/kg through subcutaneous injection, and 1.644 mg/kg through intraperitoneal injection. For research purposes, up to 1 g of venom was obtained through milking.
Sources: en.wikipedia.org
The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.
The compound is registered as a medicine in Russia, so clinical work has concentrated there. Trials elsewhere are few and generally small. This geographic concentration is a recognized limitation in evidence reviews.
Some fraction may reach the central nervous system through olfactory pathways, and this is often cited as the rationale for the nasal route. The size of that fraction in humans is not well quantified. Blood concentrations after nasal dosing are low, which complicates measurement.
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.